Publications by authors named "Fuad V Shammas"
Article Synopsis
- The study aimed to determine how the presence of disseminated tumor cells (DTCs) in bone marrow, measured by specific mRNA markers (TWIST1, CK19, hMAM), impacts prognosis in early breast cancer patients.
- Out of 191 patients, those with elevated TWIST1 levels showed a higher likelihood of systemic relapse, with significant differences in recurrence-free survival and overall survival when compared to patients without these markers.
- The findings suggest that detecting these DTCs using the multimarker panel can provide independent predictive value for clinical outcomes in breast cancer, regardless of adjuvant treatment.
Purpose: To study the prognostic significance of elevated cytokeratin 19 (CK19) mRNA levels in the bone marrow (BM) of operable breast cancer patients.
Patients And Methods: From 1998 to 2000, BM was collected from 195 consecutive breast cancer patients immediately prior to surgery and from 34 healthy volunteers. The patients received surgical and adjuvant treatment according to national guidelines at the time.
The immunomodulatory activities of recombinant human interleukin-11 (rhIL-11) were investigated in a clinical trial among patients with hematological malignancy, randomized to either rhIL-11 or placebo throughout chemotherapy. Daily serum concentrations of sTNFRI, IL-6, IL-8, TNFalpha, and CRP were measured. Higher sTNFRI levels [mean pg/ml (95% CI)] were detected in patients receiving rhIL-11 compared to placebo [1749.
View Article and Find Full Text PDFConventional therapies for primary chronic cold agglutinin disease (CAD) are ineffective, but remissions after treatment with the anti-CD20 antibody rituximab have been described in a small, prospective trial and in some case reports. In this study we report on 37 courses of rituximab administered prospectively to 27 patients. Fourteen of 27 patients responded to their first course of rituximab, and 6 of 10 responded to re-treatment.
View Article and Find Full Text PDF